2,324 results match your criteria Small Cell Carcinoma of the Bladder


Correlations Between Progression-free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-analysis.

Clin Pharmacol Ther 2020 Jun 21. Epub 2020 Jun 21.

GlaxoSmithKline, Collegeville, PA, USA.

PD-1/PD-L1 immune checkpoint blockade (ICB) has improved overall survival (OS) in solid tumor trials; however, parallel improvements in RECIST-based surrogate endpoints, progression-free survival (PFS) and objective response rate (ORR), are not always observed. Here, we assess the surrogacy of PFS/ORR for OS with ICB therapy across advanced/metastatic tumors. In a trial-level analysis (N = 40 randomized trials), PFS, ORR, and OS treatment effects were correlated (Spearman's rho). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpt.1956DOI Listing

Comparative genomics of high grade neuroendocrine carcinoma of the cervix.

PLoS One 2020 16;15(6):e0234505. Epub 2020 Jun 16.

Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.

In order to improve treatment selection for high grade neuroendocrine carcinomas of the cervix (NECC), we performed a comparative genomic analysis between this rare tumor type and other cervical cancer types, as well as extra-cervical neuroendocrine small cell carcinomas of the lung and bladder. We performed whole exome sequencing on fresh-frozen tissue from 15 NECCs and matched normal tissue. We then identified mutations and copy number variants using standard analysis pipelines. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0234505PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297329PMC

Chemoablation in Urothelial Carcinoma: A Systematic Review and Future Perspectives.

Urology 2020 Jun 12. Epub 2020 Jun 12.

Department of Urology, Loma Linda University Health, Loma Linda, CA. Electronic address:

Chemoablation is an emerging treatment for urothelial carcinomas. This review provides an overview of the evidence for intracavitary chemoablation in the treatment of urothelial carcinomas. The benefits of such agents include a reduction in morbidity and diseased organ preservation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2020.05.066DOI Listing

Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer.

iScience 2020 Jun 27;23(6):101201. Epub 2020 May 27.

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

We report a comprehensive molecular analysis of 34 cases of small cell carcinoma (SCC) and 84 cases of conventional urothelial carcinoma (UC), with The Cancer Genome Atlas cohort of 408 conventional UC bladder cancers used as the reference. SCCs showed mutational landscapes characterized by nearly uniform inactivation of TP53 and were dominated by Sanger mutation signature 3 associated with loss of BRCA1/2 function. SCCs were characterized by downregulation of luminal and basal markers and were referred to as double-negative. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.isci.2020.101201DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286965PMC

Prognostic significance of non-urothelial carcinoma of bladder: analysis of nationwide hospital-based cancer registry data in Japan.

Jpn J Clin Oncol 2020 May 29. Epub 2020 May 29.

Department of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan.

Objectives: To identify the prognosis of pure non-urothelial carcinoma (non-UC) of bladder and to compare them with those of pure urothelial carcinoma (UC).

Methods: We used Japan's nationwide hospital-based cancer registry data to extract histologically confirmed pure non-UC and UC cases of bladder diagnosed in 2008-2009. We estimated the 5-year overall survival (OS) by a Kaplan-Meier analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyaa072DOI Listing

Radical cystectomy improves survival in patients with stage T1 squamous cell carcinoma and neuroendocrine carcinoma of the urinary bladder.

Eur J Surg Oncol 2020 May 12. Epub 2020 May 12.

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.

Background: Radical cystectomy (RC) is often performed for T1 variant histology bladder cancer (VHBC), based on weak clinical evidence. We tested for cancer specific survival (CSS) differences after RC between T1 VHBC vs. urothelial carcinoma of the urinary bladder (UBC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejso.2020.05.006DOI Listing

Portal Vein Thrombosis Associated with Trousseau Syndrome due to Urinary Bladder Squamous Cell Carcinoma in a Liver Cirrhosis Patient.

Intern Med 2020 May 23. Epub 2020 May 23.

Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Japan.

A 75-year-old woman with liver cirrhosis was admitted for treatment of portal vein thrombosis (PVT). Computed tomography (CT) showed PVT, massive ascites, and multiple abdominal organ embolism. Blood tests revealed a decreased liver function (Child-Pugh grade C). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.4112-19DOI Listing

Targeted drug delivery systems: synthesis and in-vitro bioactivity and apoptosis studies of gemcitabine-carbon dots conjugates.

Biomed Mater 2020 May 22. Epub 2020 May 22.

Institute of Marine Biotechnology, Universiti Malaysia Terengganu, Kuala Terengganu, Terengganu, MALAYSIA.

Gemcitabine is used to treat various cancers like breast, pancreatic, non-small lung carcinoma, ovarian, bladder and cervical cancers. Gemcitabine (GEM), however, has the problems of non-selectivity. Water-soluble, fluorescent and mono-dispersed carbon dots (CDs) were fabricated using sucrose by ultrasonic method. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1088/1748-605X/ab95e1DOI Listing
May 2020
3.697 Impact Factor

Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study.

Ann Transl Med 2020 Apr;8(7):482

Department of Orthopaedics, Zhejiang Provincial Key Laboratory of Orthopaedics, The Second Affiliated Hospital, and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, China.

Background: Bones are one of the most common metastatic sites for solid malignancies. Bone metastases can significantly increase mortality and decrease the quality of life of cancer patients. In the United States, around 350,000 people die each year from bone metastases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2020.03.55DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210217PMC

Expression of novel neuroendocrine marker insulinoma-associated protein 1 (INSM1) in genitourinary high-grade neuroendocrine carcinomas: An immunohistochemical study with specificity analysis and comparison to chromogranin, synaptophysin, and CD56.

Pathol Res Pract 2020 Jun 26;216(6):152993. Epub 2020 Apr 26.

Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, USA. Electronic address:

Confirmation of genitourinary high-grade neuroendocrine carcinomas (GU-HGNECs) often requires immunohistochemical staining. Here we evaluated a novel neuroendocrine marker, insulinoma-associated protein 1 (INSM1), in GU-HGNECs with comparison to chromogranin, synaptophysin and CD56. Immunohistochemical expression of INSM1, chromogranin, synaptophysin, and CD56 was evaluated in 39 GU-HGNECs using full tissue sections [4 in kidney, 28 in urinary bladder, and 7 in prostate; 31 small cell carcinomas (SmCCs), 6 large cell neuroendocrine carcinomas (LCNECs), 2 mixed SmCC-LCNECs]. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2020.152993DOI Listing
June 2020
1.562 Impact Factor

Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis.

J Clin Med 2020 May 5;9(5). Epub 2020 May 5.

Department of Medical and Surgical Sciences, S.Orsola-Malpighi University Hospital, 40138 Bologna, Italy.

There is scant evidence about optimal management of poorly differentiated neuroendocrine carcinoma of the bladder (BNEC). We performed a multicenter retrospective study on BNEC patients from 13 Italian neuroendocrine-dedicated centers to analyze strategies associated with better outcomes. Mixed adeno-neuroendocrine carcinomas (MANEC) were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm9051351DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290869PMC

Gallbladder Neuroendocrine Carcinoma: A Rare Endocrine Tumor.

Cureus 2020 Mar 31;12(3):e7487. Epub 2020 Mar 31.

Internal Medicine, Indiana University Health, Indianapolis, USA.

Gallbladder neuroendocrine neoplasms (GB-NEN) are very rare neuroendocrine tumors (NETs). GB-NEN can present as carcinoid or typical/atypical carcinoid or small cell carcinoma. Most of the GB-NENs present as gall bladder polyps or stones with right upper quadrant pain, nausea and non-specific symptoms which leads to clinical misdiagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.7487DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192559PMC

Synchronous high-grade bladder carcinoma associated with chronic lymphocytic leukemia: A rare entity in Indian literature.

J Cancer Res Ther 2020 Jan-Mar;16(1):180-182

Department of Pathology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.

B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) is one of the common lymphoproliferative disorders with an increased risk of developing subsequent neoplasms of epithelial and mesenchymal origin. The decreased immunity and B-cell dysfunction in CLL probably accounts for this emergence of secondary malignancy. Breast, brain, skin and prostate tumors have been reported as usual coincident malignancies of CLL, while in occasional cases CLL may occur with malignancies of other solid organs, such as skin, lung, heart, and prostate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jcrt.JCRT_642_16DOI Listing

Extrapulmonary poorly differentiated NECs, including molecular and immune aspects.

Endocr Relat Cancer 2020 Jul;27(7):R219-R238

Department of Gastroenterology and Medical Oncology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France.

Patients with extrapulmonary poorly differentiated neuroendocrine carcinomas (EP-PD-NECs) have a poor prognosis. Surgery is offered for those with localised disease, but the majority of patients present with advanced disease. Treatment strategies adopted are analogous to that of high grade NECs of the lung, with platinum/etoposide-based regimens advocated in the first-line setting for advanced disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-19-0483DOI Listing

Routine gynecological ultrasound: look at the bladder and the ureters!

Facts Views Vis Obgyn 2020 Mar 27;11(4):347-351. Epub 2020 Mar 27.

Department of Obstetrics & Gynecology, RZ Tienen, Belgium.

Background: To illustrate the technical feasibility and diagnostic value of including the assessment of the bladder and the ureters during a standard transvaginal ultrasound examination.

Methods: We present four cases illustrating ureter and bladder pathology diagnosed by transvaginal ultrasound.

Results: In a first case, transvaginal ultrasonography in a woman with lower abdominal pain showed a calculus in the left distal ureter. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162668PMC

A rare case of small cell neuroendocrine tumor of the urinary bladder.

Indian J Pathol Microbiol 2020 Apr-Jun;63(2):298-300

Department of Urology, Lourdes Hospital, Kochi, Kerala, India.

Small cell neuroendocrine tumor of the bladder is a rare tumor characterized by poor differentiation and high aggressiveness. Very few cases worldwide have been reported till date. Recent literature shows equivalent survival data for localized disease treated with chemoradiotherapy combined with either bladder sparing surgery or radical cystectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/IJPM.IJPM_692_18DOI Listing

Small Cell Carcinoma of Bladder; Still A Diagnostic and Therapeutic Challenge: Seven Years of Experience and Follow-up in A Referral Center.

Urol J 2020 06 23;17(4):363-369. Epub 2020 Jun 23.

Hasheminejad Kidney Center(HKC), Iran University of Medical Sciences(IUMS), Tehran, Iran.

Purpose: To report clinical, histopathological, and treatment features of small cell carcinoma of (SmccB) bladder during 7 years in a referral center.

Methods: The clinical, histopathological features, treatment modalities, and outcome of all patients with bladder SmccB treated between 2009 and 2016 who were managed in Hasheminejad Kidney Center (HKC) were retrospectively collected.

Results: Thirteen patients were diagnosed and managed with SmccB. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.22037/uj.v0i0.5289DOI Listing

Differentiation of Urothelial Carcinoma into Two Distinct Subtypes, Glandular and Squamous, in Three Different Organs.

Cureus 2020 Mar 15;12(3):e7280. Epub 2020 Mar 15.

Division of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, LBN.

Urothelial carcinoma (UC) is a unique entity with different histological variants: squamous, glandular, small cell, micropapillary, sarcomatoid, and plasmacytoid. Each of those subtypes behaves differently. As such, and in many scenarios, an accurate histological diagnosis is of paramount importance to dictate the therapeutic approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.7280DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158603PMC

[Diagnostic and prognostic markers of renal cell carcinoma].

G Ital Nefrol 2020 Apr 9;37(2). Epub 2020 Apr 9.

UO di Patologia Clinica e Centro di Medicina Molecolare, Policlinico "Ospedali Riuniti" di Foggia, Dipartimento di Scienze Mediche e Chirurgiche, Università degli Studi di Foggia, Foggia, Italia.

Renal cell carcinoma (RCC) is the deadliest of all urogenital tumors, whereas it is the third for incidence after prostate and bladder cancer. An early diagnosis of RCC allows patients affected to be promptly treated with effective therapies, significantly increasing their survival rate. In addition, an early and accurate diagnosis avoids inadequate treatment, helps predict disease progression and establish the most appropriate treatments. Read More

View Article

Download full-text PDF

Source

[Large nested variant of urothelial carcinoma of urinary bladder: a clinicopathological analysis of five cases].

Zhonghua Bing Li Xue Za Zhi 2020 Apr;49(4):317-323

Department of Pathology, Zhejiang Provincial People's Hospital & People's Hospital of Hangzhou Medical College, Hangzhou 310014, China.

To investigate the clinicopathologic features, diagnosis and differential diagnosis of large nested variant of urothelial carcinoma (LNUC) of urinary bladder. The clinical and pathologic data of five cases of LNUC of urinary bladder diagnosed between January 2014 and December 2018 at the Department of Pathology, Zhejiang Provincial People's Hospital were analyzed by immunohistochemistry (IHC) and Sanger sequencing. The relevant literature was reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.cn112151-20190721-00405DOI Listing

[Paraganglioma of urinary bladder: a clinicopathological features analysis of 23 cases].

Zhonghua Bing Li Xue Za Zhi 2020 Apr;49(4):311-316

Department of Pathology, Fujian Provincial Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou 350001, China.

To investigate the clinicopathological features, diagnosis, differential diagnosis and immunohistochemical (IHC) characteristics of paraganglioma of urinary bladder (PUB). The clinical and pathological data of 23 cases of PUB were collected at the Second Affiliated Hospital of Fujian Medical University (7 cases); Fujian Provincial Hospital (8 cases); Fujian Medical University Union Hospital (6 cases); and First Affiliated Hospital of Fujian Medical University (2 cases) from May 2010 to November 2018. IHC staining for CK, GATA3, CD56, Syn, CgA, S-100 protein, HMB45, SDHB, OCT3/4 and Ki-67 was done using EliVision method; and the relevant literature was reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.cn112151-20190928-00535DOI Listing

Use of oral paclitaxel for the treatment of bladder tumors in dogs.

J Vet Med Sci 2020 May 3;82(5):527-530. Epub 2020 Apr 3.

Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University, Seoul 08826, Republic of Korea.

An oral paclitaxel formulation that overcomes the hypersensitivity reaction of paclitaxel has been evaluated for safety and efficacy in humans, but not in dogs. We present the first case report on the use of oral paclitaxel in dogs. In this study, oral paclitaxel was well-tolerated in four dogs with either transitional cell carcinoma or prostate cancer; adverse effects were limited to mild neutropenia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1292/jvms.19-0578DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273596PMC

[Effect of down-regulation of fatty acid synthase expression on proliferation, migration and invasion of bladder carcinoma UMUC3 cell lines].

Zhongguo Ying Yong Sheng Li Xue Za Zhi 2019 Nov;35(6):543-547

Department of Medical Oncology, the Affiliated Zhuzhou Hospital Xiangya Medical College Central South University, Zhuzhou 412000.

Objective: To investigate the effects of fatty acid synthase (FASN) on proliferation, migration and invasion of bladder cancer UMUC3 cell lines and possible mechanism.

Methods: The expression levels of FASN protein in 30 cases of bladder cancer and 15 cases of normal bladder tissues were detected by Immunohistochemistry. FASN siRNA and nonsense siRNA were transfected into UMUC3 cell lines by lipofectamine 2000 respectively, and the stable siFASN and siControl cell lines were successfully obtained after screening and identification for several times. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12047/j.cjap.5868.2019.119DOI Listing
November 2019

Small-cell neuroendocrine carcinoma of the urinary bladder: A case report.

Int J Health Sci (Qassim) 2020 Mar-Apr;14(2):53-55

Department of Pathology, Shifa International Hospital, Islamabad, Pakistan.

Primary neuroendocrine carcinomas of the urinary bladder are rare. A 60-year-old male presented with gross hematuria for the past 3 months. Diagnostic flexible cystoscopy revealed a papillary lesion above the right ureteric orifice. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069666PMC

Effective Treatments for Bladder Cancer Affecting CXCL9/CXCL10/CXCL11/CXCR3 Axis: A Review.

Oman Med J 2020 Mar 11;35(2):e103. Epub 2020 Mar 11.

Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.

Bladder cancer (BC) originates mainly from the epithelial compartment of the bladder, which is defined as transitional cell carcinoma or urothelial cell carcinoma. About 70% of patients with BC will survive five years from diagnosis. Previous studies revealed that the immune system and its mediators, particularly chemokines, play a crucial role in modulating responses against BC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5001/omj.2020.21DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064791PMC

Neuroendocrine tumors of the urinary bladder A case series and review of the literature.

Ann Ital Chir 2020 ;91:65-68

Neuroendocrine carcinoma cases, more frequent in the GI tract, have rarely been reported in extrapulmonary areas. Neuroendocrine carcinoma of the bladder is one of the malignancies with a poor prognosis, which is expected to cause rapid metastases. In addition, neuroendocrine carcinoma of the bladder constitutes < 1% of all bladder carcinomas. Read More

View Article

Download full-text PDF

Source
January 2020

P16 as a marker of carcinoma in effusions and peritoneal washing.

BMC Cancer 2020 Mar 17;20(1):225. Epub 2020 Mar 17.

Pathology Department of Brasília University, Brasília, Brazil.

Background: Considering the potential of p16 as a marker for diagnosis, prognosis and therapeutic response, the aim of this study was to assess its presence, via immunocytochemistry, in metastatic carcinoma of different primary sites and histological types obtained from effusions and peritoneal washings. A total of 118 samples including 85 of metastatic carcinoma and 33 samples of benign effusion/peritoneal washing were prepared by the plasma/thromboplastin method. Immunocytochemistry reactions were performed on cell block sections using antibodies against p16, claudin-4, MOC-31, calretinin, HBME and CD68. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-020-6670-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076945PMC

Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis.

PLoS One 2020 13;15(3):e0230272. Epub 2020 Mar 13.

Small Animal Clinic, University of Veterinary Medicine Hannover, Hannover, Germany.

Canine prostate adenocarcinoma (PAC) and transitional cell carcinoma (TCC) of prostate and urinary bladder are highly invasive and metastatic tumors of closely neighbored organs. Cell lines are valuable tools to investigate tumor mechanisms and therapeutic approaches in vitro. PAC in dogs is infrequent, difficult to differentiate from TCC and usually characterized by poor prognosis, enhancing the value of the few available cell lines. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0230272PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069630PMC

Survival of Contemporary Patients With Non-metastatic Small-cell Carcinoma of Urinary Bladder, According to Alternative Treatment Modalities.

Clin Genitourin Cancer 2019 Dec 13. Epub 2019 Dec 13.

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.

Background: The objective of this study was to test the effect of chemotherapy and/or radical cystectomy (RC) and/or radiotherapy (RT) on survival of patients with non-metastatic small-cell carcinoma of the urinary bladder (SCCUB).

Materials And Methods: Within the Surveillance, Epidemiology, and End Results registry (2001-2016), we identified patients with non-metastatic (T1-4, N0, M0) SCCUB. Treatment was defined as: chemotherapy alone, chemotherapy + RC, and chemotherapy + RT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.12.001DOI Listing
December 2019

Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study.

Clin Genitourin Cancer 2020 Feb 8. Epub 2020 Feb 8.

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Background: Nonurothelial carcinoma (UC) malignancies have traditionally been considered to have a more aggressive clinical course, and little is known about their response to neoadjuvant therapy. We examined the effect of neoadjuvant chemotherapy (NAC) on a large population of patients with bladder cancer (BCa) with different histologic variants (HVs).

Patients And Methods: We relied on a retrospective, multicenter database of 2858 patients with BCa who had undergone radical cystectomy with or without NAC from 1990 to 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2020.01.007DOI Listing
February 2020
1.693 Impact Factor

A California Cancer Registry Analysis of Urothelial and Non-urothelial Bladder Cancer Subtypes: Epidemiology, Treatment, and Survival.

Clin Genitourin Cancer 2020 Jun 16;18(3):e330-e336. Epub 2020 Jan 16.

Department of Urology, University of California Irvine, Orange, CA.

Introduction: We evaluated epidemiologic trends and survival for bladder cancer histologic subtypes in California patients by comparing urothelial carcinoma of the bladder (UCB) and non-urothelial subtypes including squamous cell carcinoma (SCC), adenocarcinoma (ADC), and small-cell carcinoma (SmCC).

Materials And Methods: The California Cancer Registry (CCR) was queried for incident bladder cancer cases from 1988 to 2012. Epidemiologic trends based on tumor histology were described. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2020.01.002DOI Listing

Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap.

Hum Pathol 2020 Apr 3;98:81-88. Epub 2020 Mar 3.

Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, 35249, USA. Electronic address:

Flat urothelial lesions with atypia may pose significant diagnostic challenges. Given frequent increased proliferation rates in florid reactive urothelial atypia and limited studies on the interpretation of p53 stains in the urothelium (following current standard guidelines for correlation with P53 mutation status), we sought to further study the discriminatory value of Ki-67 and p53 for florid reactive urothelial atypia versus urothelial carcinoma in situ (CIS). Bladder specimens diagnosed as reactive urothelial atypia (n = 40) and CIS (n = 40) were assessed by immunohistochemical staining with antibodies for Ki-67, p53, CD44, and CK20. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2020.02.008DOI Listing

Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.

Am J Health Syst Pharm 2020 Feb;77(5):346-351

University of Kentucky College of Pharmacy, Lexington, KY.

Purpose: To provide an overview of fibroblast growth factor receptor (FGFR) gene alterations and the pharmacology, clinical effectiveness, dosage and administration, cost, and place in therapy of erdafitinib in bladder cancer.

Summary: Erdafitinib (Balversa, Janssen Pharmaceuticals) is a novel pan-FGFR inhibitor recently approved for the treatment of patients with advanced urothelial cancer with specific FGFR genetic alterations who have received at least one prior platinum-containing regimen. Erdafitinib binding to the FGFR2 and FGFR3 receptors inhibits FGF activity, resulting in cell death. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ajhp/zxz329DOI Listing
February 2020

Enterovesical fistula secondary to transitional cell carcinoma of the bladder in a 20 years old patient: A rare entity.

Urol Case Rep 2020 May 17;30:101123. Epub 2020 Jan 17.

Department of Urology, Mohammed IV University Medical Center, Faculty of Medicine and Pharmacy, Mohammed the First University Oujda, Morocco.

Bladder cancers are not very common in young people under 20 years, especially with an atypical presentation such as faecaluria due to enterovesical fistula. This report describes the case of a 20 years old man who was diagnosed with a mass involving the small intestine and bladder during the course of investigations for faecaluria and abdominal pain. Histopathological examination of the biopsies during cystoscopy revealed: muscle invasive transitional cell carcinoma, while the computerized tomography scan had confirmed the enterovesical fistula. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eucr.2020.101123DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997819PMC

Human papillomavirus and urinary bladder cancer revisited.

APMIS 2020 Feb 28;128(2):72-79. Epub 2020 Jan 28.

Department of Urology, Aarhus University Hospital, Aarhus, Denmark.

This review aims to present data on the association between human papillomavirus (HPV) and urinary bladder cancer (BC), especially of the subtype squamous cell carcinoma (SCC). Furthermore, the current data on the relation between p16, HPV, and BC are reviewed. PubMed was searched for 'Humans' [MESH] AND 'Papillomaviridae' [MESH] AND 'Urinary Bladder Neoplasms' [MESH], resulting in 157 potential articles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apm.13016DOI Listing
February 2020

New insight in endocrine-related adverse events associated to immune checkpoint blockade.

Best Pract Res Clin Endocrinol Metab 2020 Jan 11;34(1):101370. Epub 2019 Dec 11.

Department of Clinical and Experimental Medicine, University of Pisa, 56126, Pisa, Italy. Electronic address:

Anticancer immunotherapy, in the form of immune checkpoint inhibition, is a paradigm shift that has transformed the care of patients with different types of solid and hematologic cancers. The most notable improvements have been seen in patients with melanoma, non-small-cell lung, bladder, renal, cervical, urotherial, and colorectal cancers, Merkel cell carcinoma, and Hodgkin lymphoma. Monoclonal antibodies (mAbs) targeting immune checkpoints (i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beem.2019.101370DOI Listing
January 2020

The emerging landscape of germline variants in urothelial carcinoma: Implications for genetic testing.

Cancer Treat Res Commun 2020 Jan 7;23:100165. Epub 2020 Jan 7.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, DANA 1230, Boston, MA 02215, United States. Electronic address:

Urothelial carcinoma (UC) of the bladder and upper tract (ureter, renal pelvis) is one of the most frequently occurring malignancies. While the majority of UC are chemically induced by smoking, accumulating evidence from genetic studies have demonstrated a small, but consistent impact of heritable gene variants and family history of UC on the development of the disease. Beyond the established association between upper tract UC and germline mismatch DNA repair defects as a defining feature of Lynch syndrome, newer investigations focusing on moderate- and high-risk cancer-related gene variants in DNA damage repair and other signaling pathways are expanding our knowledge on the heritable genetic basis of UC, opening new avenues in the breadth of genetic testing and in clinical counseling of these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100165DOI Listing
January 2020

Clinical and pathological characteristics of bladder cancer in post brachytherapy patients.

Pathol Res Pract 2020 Mar 10;216(3):152822. Epub 2020 Jan 10.

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.

The long-term risk of secondary malignancy is a potential late effect of brachytherapy. However, the time interval, anatomic site and histopathology are not well studied. We sought to characterize the bladder cancers that developed following treatment of prostate cancer with brachytherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2020.152822DOI Listing

DLEU1: A Functional Long Noncoding RNA in Tumorigenesis.

Curr Pharm Des 2020 ;26(15):1742-1748

China Three Gorges University, School of Medicine, Yichang, 443002, Hubei, China.

Background: LncRNA DLEU1 participates in various biological processes, playing an indispensable role in the pathophysiology of human diseases, especially in tumorigenesis and other processes. Besides, it may represent a promising target for biotherapy in numerous tumors. The aim of this review was to reveal the pathophysiological functions and mechanisms of lncRNA DLEU1 in different types of cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1381612826666200122145305DOI Listing
January 2020

Disabled Homolog 2 (DAB2) Protein in Tumor Microenvironment Correlates with Aggressive Phenotype in Human Urothelial Carcinoma of the Bladder.

Diagnostics (Basel) 2020 Jan 20;10(1). Epub 2020 Jan 20.

Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.

Disabled homolog-2 () has been reported to be a tumor suppressor gene. However, a number of contrary studies suggested that DAB2 promotes tumor invasion in urothelial carcinoma of the bladder (UCB). Here, we investigated the clinical role and biological function of DAB2 in human UCB. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/diagnostics10010054DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168324PMC
January 2020

Outcomes of bladder preservation therapy on survival in patients with muscle-invasive bladder cancer.

Arch Esp Urol 2020 Jan;73(1):41-46

Department of Medical Oncology. Gülhane Training and Research Hospital. Ankara. Turkey.

Introduction: The standard of care in muscle invasive bladder cancer is radical cystectomy; however; transurethral resection (TUR) followed by external radiotherapy and systemic chemotherapy demonstrates comparable results with radical cystectomy in terms of local control and survival rates.

Objectives: To evaluate our results of multimodality bladder preservation therapy (BPT) in patients who had muscle-invasive bladder cancer and were reluctant to radical cystectomy. METHODS: The retrospective analysis of twenty-three patients with stage T2 transitional cell bladder cancer that were consecutively treated with BPT was performed. Read More

View Article

Download full-text PDF

Source
January 2020

Simultaneous expression of TTF1 and GATA3 in a lung biopsy sample: confusion in diagnostic pathology.

Int J Clin Exp Pathol 2019 1;12(9):3613-3619. Epub 2019 Sep 1.

Cancer Center, Daping Hospital, Army Medical University No. 10 Changjiang Zhilu, Yuzhong District, Chongqing 400042, China.

Background: In daily work, pathologists often use TTF1 and GATA3 in the differential diagnosis of primary lung adenocarcinoma (TTF1+ GATA3-) and metastatic bladder cancer (or breast cancer) (TTF1- GATA3+). However, we encountered a small lung biopsy sample of TTF1+ GATA3+ (clinically suggesting both lung and bladder occupancy), and the dyeing results caused us great confusion; thus, we intended to determine the expressions of TTF1 and GATA3 in lung and bladder cancer by expanding the sample.

Methods: The study included a complete case report and the tissue microarrays including pulmonary squamous cell carcinomas (n = 55), lung adenocarcinomas (n = 47), high-grade (n = 68) and low-grade (n = 43) urothelial carcinomas of the bladder. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949810PMC
September 2019

Primary small cell neuroendocrine carcinoma combined with squamous carcinoma of the ureter after renal transplantation: a rare case report.

Int J Clin Exp Pathol 2019 1;12(4):1357-1362. Epub 2019 Apr 1.

Department of Pathology, The First Affiliated Hospital of Sun Yat-sen University Guangzhou, Guangdong, China.

A 47-year-old female presented with a 1-month history of painless gross hematuria after undergoing kidney transplant 4 years. Computed tomography revealed mass-like soft tissue density in the middle-lower portion of the right autologous ureter, which was up to the upper margin of the fourth lumbar vertebra, down to the distal ureter near the entrance of the bladder. The patient underwent right autologous nephroureterectomy resection. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947063PMC

Urinary Microbiome Evaluation in Patients Presenting with Hematuria with a Focus on Exposure to Tobacco Smoke.

Res Rep Urol 2019 27;11:359-367. Epub 2019 Dec 27.

Cell and Molecular Biology Laboratory, Lahey Hospital & Medical Center, Burlington, MA 01805, USA.

Purpose: To better characterize the urinary microbiome in males and contribute to overall understanding of the urinary microbiota specifically in patients undergoing evaluation for possible bladder cancer, stratified by risk exposure to smoking.

Patients And Methods: Recruitment of 43 male patients in a sequential manner presenting for hematuria evaluation to a single institution was undertaken. Mid-stream urine specimen pellets were processed through a DNA isolation protocol before undergoing PCR amplification, purification, and 16S rRNA gene sequencing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/RRU.S233386DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938191PMC
December 2019

Lysophosphatidic Acid Upregulates Recepteur D'origine Nantais Expression and Cell Invasion via Egr-1, AP-1, and NF-κB Signaling in Bladder Carcinoma Cells.

Int J Mol Sci 2020 Jan 1;21(1). Epub 2020 Jan 1.

Research Institute of Medical Sciences, Chonnam National University Medical School, Gwangju 501-190, Korea.

Muscle invasive bladder carcinoma is a highly malignant cancer with a high mortality rate, due to its tendency to metastasize. The tyrosine kinase recepteur d'origine nantais (RON) promotes bladder carcinoma metastasis. Lysophosphatidic acid (LPA) is a phospholipid derivative, which acts as a signaling molecule to activate three high affinity G-protein coupled receptors, LPA1, LPA2, and LPA3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21010304DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981588PMC
January 2020

[Inverted Variant of Urothelial Carcinoma of the Urinary Bladder : A Case Report].

Hinyokika Kiyo 2019 Nov;65(11):463-467

The Department of Molecular Pathology, Shinshu University School of Medicine.

A 69-year-old male complained of gross hematuria. Cystoscopy revealed a papillary pedunculated tumor. The tumor was approximately 4 cm in length, and mimicked an inverted papilloma with a small stalk and smooth surface, located on the bladder trigone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14989/ActaUrolJap_65_11_463DOI Listing
November 2019

Prostate specific membrane antigen (PSMA) in urothelial cell carcinoma (UCC) is associated with tumor grading and staging.

J Cancer Res Clin Oncol 2020 Feb 2;146(2):305-313. Epub 2020 Jan 2.

Department of Urology and Pediatric Urology, University Hospital Marburg, Marburg, Germany.

Introduction: Prostate specific membrane antigen (PSMA) has become a target for radionuclide imaging and therapy. Previous studies have shown that the expression of PSMA is not specific to prostate tissue. In this study we examine the expression of PSMA in urothelial cell carcinoma (UCC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-019-03113-9DOI Listing
February 2020

ARID1A upregulation predicts better survival in patients with urothelial bladder carcinoma.

J Int Med Res 2019 Dec 31:300060519895687. Epub 2019 Dec 31.

Department of Urology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Objective: AT-rich interactive domain-containing protein 1A (ARID1A) is frequently mutated or deficient in various types of tumors. However, the role of ARID1A in bladder cancer remains unclear. We aimed to evaluate ARID1A expression and its biological role and correlation with prognosis in patients with urothelial bladder carcinoma (BUC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0300060519895687DOI Listing
December 2019

Small cell carcinoma of the bladder presenting with paraneoplastic syndrome of inappropriate antidiuretic hormone.

BMJ Case Rep 2019 Dec 29;12(12). Epub 2019 Dec 29.

Internal Medicne, SAUSHEC, Fort Sam Houston, Texas, USA.

Small cell carcinoma (SCC) of the bladder is a rare malignancy, representing less than 1% of bladder cancers diagnosed annually in the USA. In contrast to SCC of the lung, paraneoplastic syndromes are rarely documented in cases of extrapulmonary SCCs, particularly those of genitourinary origin. We present a case of SCC of the bladder presenting with paraneoplastic syndrome of inappropriate antidiuretic hormone, which resolved after treatment with sequential chemoradiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2019-232128DOI Listing
December 2019

Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group.

Clin Genitourin Cancer 2019 Dec 5. Epub 2019 Dec 5.

Department of Medical Oncology, Hôpital Européen Georges Pompidou, Paris, France; Association pour la Recherche et les Thérapeutiques Innovantes en Cancérologie, Paris, France; University René Descartes, Paris, France.

Background: Neuroendocrine carcinoma of the urinary bladder (NCUB) is rare, accounting for < 1% of bladder cancer cases, with scarce reported data available.

Materials And Methods: We retrospectively reviewed the data from patients with NCUB treated at French institutions. The objectives were to describe the patient characteristics, treatments received, and outcomes (ie, disease-free survival [DFS], progression-free survival, overall survival [OS]) and investigate the prognostic factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.11.014DOI Listing
December 2019